UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Clinical lymphoma, myeloma and leukemia, ISSN 2152-2650, 10/2019, Volume 19, Issue 10, pp. e220 - e221
Journal Article
Brain (London, England : 1878), ISSN 0006-8950, 07/2019, Volume 142, Issue 7, pp. 1894 - 1904
phase 3 | migraine | safety/tolerability | lasmiditan | efficacy | Neurosciences | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Double-Blind Method | Cardiovascular Diseases - drug therapy | Humans | Risk Factors | Male | Migraine Disorders - drug therapy | Dose-Response Relationship, Drug | Young Adult | Serotonin Receptor Agonists - therapeutic use | Cardiovascular Diseases - complications | Pyridines - adverse effects | Benzamides - therapeutic use | Time Factors | Piperidines - therapeutic use | Piperidines - adverse effects | Migraine Disorders - complications | Adult | Female | Benzamides - adverse effects | Pyridines - therapeutic use | Index Medicus | Abridged Index Medicus | Clinical Trial | Editor's Choice | safety | tolerability
Journal Article
Veterinary sciences, 10/2020, Volume 7, Issue 4, p. 152
Journal Article
Epilepsia (Copenhagen), ISSN 0013-9580, 06/2020, Volume 61, Issue 6, pp. 1099 - 1108
antiepileptic drugs | DRESS | safety/tolerability | refractory epilepsy | cenobamate | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Convulsions & seizures | Phenobarbital | Epilepsy | Titration | Plasma levels | Safety | Eosinophilia | Phenytoin | Seizures | Index Medicus | safety | tolerability | Full‐length Original Research
Journal Article
Antimicrobial agents and chemotherapy, ISSN 0066-4804, 08/2018, Volume 62, Issue 8
Journal Article
European journal of pharmaceutical sciences, ISSN 0928-0987, 02/2021, Volume 157, pp. 105646 - 105646
Journal Article
Epilepsy research, ISSN 0920-1211, 01/2021, Volume 169, pp. 106478 - 106478
Journal Article
Epilepsy research, ISSN 0920-1211, 11/2020, Volume 167, pp. 106369 - 106369
Journal Article
OncoTargets and therapy, ISSN 1178-6930, 2020, Volume 13, pp. 12539 - 12547
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 03/2018, Volume 154, Issue 4, pp. 989 - 997
Journal Article
Epilepsy & behavior, ISSN 1525-5050, 12/2020, Volume 113, pp. 107464 - 107464
Journal Article
AIDS research and therapy, ISSN 1742-6405, 08/2019, Volume 16, Issue 1, pp. 21 - 21
Life Sciences & Biomedicine | Infectious Diseases | Science & Technology | Anti-Retroviral Agents - therapeutic use | Prospective Studies | HIV-1 - drug effects | Humans | Middle Aged | Male | Adult | Female | HIV Infections - drug therapy | Cobicistat - therapeutic use | Drug Therapy, Combination | Viral Load - drug effects | Darunavir - therapeutic use | Medicine, Experimental | Medical research | Dosage and administration | Darunavir | Drug therapy | HIV infection | Antiviral agents | Care and treatment | Hypercholesterolemia | Analysis | Low density lipoproteins | Cholesterol | Anti-HIV agents | Rank tests | Lipoproteins (low density) | Toxicity | Antiretroviral agents | Hypertriglyceridemia | Durability | Lipids | Triglycerides | Index Medicus | AIDS/HIV | Darunavir/cobicistat | Tolerability | Adverse events | Dual | CISAI
Journal Article
Seizure (London, England), ISSN 1059-1311, 12/2020, Volume 83, pp. 197 - 202
Journal Article
Epilepsy & behavior, ISSN 1525-5050, 05/2020, Volume 106, pp. 106967 - 106967
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 2013, Volume 49, Issue 16, pp. 3412 - 3419
Hematology, Oncology and Palliative Medicine | Second line | Regorafenib | Hepatocellular carcinoma | Tolerability | Safety | Receptor kinase inhibition | Safety Second line | Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Pharmacology. Drug treatments | Tumors | Carcinoma, Hepatocellular - mortality | Humans | Middle Aged | Pyridines - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Liver Neoplasms - mortality | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Time Factors | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Adult | Female | Liver Neoplasms - pathology | Antineoplastic Agents - pharmacokinetics | Phenylurea Compounds - pharmacokinetics | Liver Neoplasms - enzymology | Pyridines - therapeutic use | Protein Kinase Inhibitors - pharmacokinetics | Pyridines - administration & dosage | Drug Administration Schedule | Europe | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Phenylurea Compounds - therapeutic use | Treatment Outcome | Carcinoma, Hepatocellular - enzymology | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Phenylurea Compounds - administration & dosage | Asia | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Aged | Neoplasm Staging | Care and treatment | Safety and security measures | Hepatoma | Index Medicus
Journal Article